Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search
  1. NCI-F Publications

Search
  1. Year Published:

Your search returned 29 results.
User Information
Export Records
  1. 1.   Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage
  2. Zhu, M.; Yi, M.; Kim, C. H.; Deng, C. X.; Li, Y.; Medina, D.; Stephens, R. M.; Green, J. E.
  3. Genome Biology. 2011, Aug 16; 12(8): 16.
  1. 2.   Two-tiered Approach Identifies a Network of Cancer and Liver Disease-related Genes Regulated by miR-122
  2. Boutz, D. R.; Collins, P. J.; Suresh, U.; Lu, M. Z.; Ramirez, C. M.; Fernandez-Hernando, C.; Huang, Y. F.; Abreu, R. D.; Le, S. Y.; Shapiro, B. A.; Liu, A. M.; Luk, J. M.; Aldred, S. F.; Trinklein, N. D.; Marcotte, E. M.; Penalva, L. O. F.
  3. Journal of Biological Chemistry. 2011, May; 286(20): 18066-18078.
  1. 3.   Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation
  2. Liu, B.; Liu, L.; Tsykin, A.; Goodall, G. J.; Green, J. E.; Zhu, M.; Kim, C. H.; Li, J. Y.
  3. Bioinformatics. 2010, Dec; 26(24): 3105-3111.
  1. 4.   The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts
  2. Aprelikova, O.; Yu, X. A.; Palla, J.; Wei, B. R.; John, S.; Yi, M.; Stephens, R.; Simpson, R. M.; Risinger, J. I.; Jazaeri, A.; Niederhuber, J.
  3. Cell Cycle. 2010, Nov; 9(21): 4387-4398.
  1. 5.   CCAAT/enhancer binding protein delta (C/EBP delta, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage
  2. Wang, J.; Sarkar, T. R.; Zhou, M.; Sharan, S.; Ritt, D. A.; Veenstra, T. D.; Morrison, D. K.; Huang, A. M.; Sterneck, E.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2010, Sep; 107(37): 16131-16136.
  1. 6.   Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel
  2. Bussey, K. J.; Chin, K.; Lababidi, S.; Reimers, M.; Reinhold, W. C.; Kuo, W. L.; Gwadry, F.; Jain, A.; Kouros-Mehr, H.; Fridly, J.; Jain, A.; Collins, C.; Nishizuka, S.; Tonon, G.; Roschke, A.; Gehlhaus, K.; Kirsch, I.; Scudiero, D. A.; Gray, J. W.; Weinstein, J. N.
  3. Molecular Cancer Therapeutics. 2006, Apr; 5(4): 853-867.
  1. 7.   Precancer in mice: Animal models used to understand, prevent, and treat human precancers
  2. Cardiff, R. D.; Anver, M. R.; Boivin, G. P.; Bosenberg, M. W.; Maronpot, R. R.; Molinolo, A. A.; Nikitin, A. Y.; Rehg, J. E.; Thomas, G. V.; Russell, R. G.; Ward, J. M.
  3. Toxicologic Pathology. 2006 34(6): 699-707.
  1. 8.   Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis
  2. Zudaire, E.; Martinez, A.; Garayoa, M.; Pio, R.; Kaur, G.; Woolhiser, M. R.; Metcalfe, D. D.; Hook, W. A.; Siraganian, R. P.; Guise, T. A.; Chirgwin, J. M.; Cuttitta, F.
  3. American Journal of Pathology. 2006, JAN; 168(1): 280-291.
  1. 9.   A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer
  2. Burger, A. M.; Gao, Y. G.; Amemiya, Y.; Kahn, H. J.; Kitching, R.; Yang, Y. L.; Sun, P.; Narod, S. A.; Hanna, W. M.; Seth, A. K.
  3. Cancer Research. 2005, NOV 15; 65(22): 10401-10412.
  1. 10.   Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity
  2. Shi, Z. D.; Liu, H. P.; Zhang, M. C.; Worthy, K. M.; Bindu, L.; Yang, D. J.; Fisher, R. J.; Burke, T. R.
  3. Bioorganic & Medicinal Chemistry. 2005, JUL 1; 13(13): 4200-4208.
  1. 11.   Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer
  2. Palmieri, D.; Halverson, D. O.; Ouatas, T.; Horak, C. E.; Salerno, M.; Johnson, J.; Figg, W. D.; Hollingshead, M.; Hursting, S.; Berrigan, D.; Steinberg, S. M.; Merino, M. J.; Steeg, P. S.
  3. Journal of the National Cancer Institute. 2005, MAY 4; 97(9): 632-642.
  1. 12.   Ring-closing metathesis of C-terminal allylglycine residues with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic as an approach to novel Grb2 SH2 domain-binding macrocycles
  2. Oishi, S.; Shi, Z. D.; Worthy, K. M.; Bindu, L. K.; Fisher, R. J.; Burke, T. R.
  3. Chembiochem. 2005, APR; 6(4): 668-674.
  1. 13.   Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic
  2. Shi, Z. D.; Karki, R. G.; Oishi, S.; Worthy, K. M.; Bindu, L. K.; Dharmawardana, P. G.; Nicklaus, M. C.; Bottaro, D. P.; Fisher, R. J.; Burke, T. R.
  3. Bioorganic & Medicinal Chemistry Letters. 2005, MAR 1; 15(5): 1385-1388.
  1. 14.   Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells
  2. Sun, R. H.; Gao, P.; Chen, L.; Ma, D. L.; Wang, J. M.; Oppenheim, J. J.; Zhang, N.
  3. Cancer Research. 2005, FEB 15; 65(4): 1433-1441.
  1. 15.   Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics
  2. Oishi, S.; Karki, R. G.; Kang, S. U.; Wang, X. Z.; Worthy, K. M.; Bindu, L. K.; Nicklaus, M. C.; Fisher, R. J.; Burke, T. R.
  3. Journal of Medicinal Chemistry. 2005, FEB 10; 48(3): 764-772.
  1. 16.   The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappa B activity in drug-sensitive MCF-7 cells
  2. Brantley, E.; Patel, V.; Stinson, S. F.; Trapani, V.; Hose, C. D.; Ciolino, H. P.; Yeh, G. C.; Gutkind, J. S.; Sausville, E. A.; Loaiza-Perez, A. I.
  3. Anti-Cancer Drugs. 2005, FEB; 16(2): 137-143.
  1. 17.   Synthesis of gold nanoparticles bearing the Thomsen-Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen
  2. Svarovsky, S. A.; Szekely, Z.; Barchi, J. J.
  3. Tetrahedron-Asymmetry. 2005, JAN 24; 16(2): 587-598.
  1. 18.   Evaluation of macrocyclic Grb2 SH2 domain-binding peptide mimetics prepared by ring-closing metathesis of C-terminal allylglycines with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic
  2. Oishi, S.; Karki, R. G.; Shi, Z. D.; Worthy, K. M.; Bindu, L.; Chertov, O.; Esposito, D.; Frank, P.; Gillette, W. K.; Maderia, M.; Hartley, J.; Nicklaus, M. C.; Barchi, J. J.; Fisher, R. J.; Burke, T. R.
  3. Bioorganic & Medicinal Chemistry. 2005 13(7): 2431-2438.
  1. 19.   Arylthioindoles, potent inhibitors of tubulin polymerization
  2. De Martino, G.; La Regina, G.; Coluccia, A.; Edler, M. C.; Barbera, M. C.; Brancale, A.; Wilcox, E.; Hamel, E.; Artico, M.; Silvestri, R.
  3. Journal of Medicinal Chemistry. 2004, DEC 2; 47(25): 6120-6123.
  1. 20.   Discovery and therapeutic potential of novel Bcl-2/Bcl-xL small-molecule inhibitors in human breast cancer
  2. Xu, L.; Wang, G.; Tang, N.; Nikolovska-Coleska, Z.; Wang, R.; Demchik, L.; Liu, M.; Zhang, M.; Roller, P.; Tomita, Y.; Yang, D.; Rae, J.; Lippman, M. E.; Wang, S.
  3. Breast Cancer Research and Treatment. 2004 88(Suppl. 1): S66, Abstract 1073-S66, Abstract 1073.
  1. 21.   An expanding appreciation of the role chemokine receptors play in cancer progression
  2. Howard, O. M. Z.; Galligan, C. L.
  3. Current Pharmaceutical Design. 2004 10(19): 2377-2389.
  1. 22.   A novel macrocyclic tetrapeptide mimetic that exhibits low- picomolar Grb2 SH2 domain-binding affinity
  2. Shi, Z. D.; Lee, K.; Liu, H. P.; Zhang, M. C.; Roberts, L. R.; Worthy, K. M.; Fivash, M. J.; Fisher, R. J.; Yang, D. J.; Burke, T. R.
  3. Biochemical and Biophysical Research Communications. 2003 310(2): 378-383.
  1. 23.   Combinatorial evolution of high-affinity peptides that bind to the Thomsen-Friedenreich carcinoma antigen
  2. Landon, L. A.; Peletskaya, E. N.; Glinsky, V. V.; Karasseva, N.; Quinn, T. P.; Deutscher, S. L.
  3. Journal of Protein Chemistry. 2003 22(2): 193-204.
  1. 24.   Overexpression of kinase suppressor of Ras upregulates the high-molecular-weight tropomyosin isoforms in ras-transformed NIH 3T3 fibroblasts
  2. Janssen, R. A. J.; Kim, P. N.; Mier, J. W.; Morrison, D. K.
  3. Molecular and Cellular Biology. 2003 23(5): 1786-1797.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel